Researchers from Therapyx Inc. and Intravacc BV assessed the potential of intranasal administration of a novel gonococcal vaccine candidate consisting of outer membrane vesicles (OMVs) and microsphere (ms)-encapsulated interleukin-12 (IL-12 ms). It was previously demonstrated that female mice can be immunized intravaginally with gonococcal OMVs plus IL-12 ms to induce anti-gonococcal antibodies and resistance to genital tract challenge with live Neisseria gonorrhoeae.
Trex Bio Inc. has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly & Co. to develop novel therapies for the treatment of immune-mediated diseases.
Researchers from Neoleukin Therapeutics Inc. have described NEO-TRA1, a novel CD25-targeted de novo non-α agonist of the IL-2 receptor (IL-2R) designed to selectively expand Tregs.
Researchers at the University of Cape Town have compared the T-cell responses of individuals who were infected with Mycobacterium tuberculosis but were able to control the infection to those who developed active disease. The researchers wrote that the shared antigens in controllers “can be considered as high-priority targets for future vaccine development.” Their results were published online in Nature Medicine on Jan. 5, 2023. In their experiments, the team first sequenced the CDR3β region of the T-cell repertoire in a total of 166 individuals with M. tuberculosis infection who progressed to either TB or controlled infection.
Ventus Therapeutics Inc. has nominated a potential first-in-class cyclic GMP-AMP synthase (cGAS) inhibitor, VENT-03, as the company’s first development candidate directed against cGAS.
After comparing the response to the two types of vaccines for the respiratory syncytial virus (RSV) based on its fusion protein (F), prefusion (pre-F) versus postfusion (post-F) vaccines, scientists at the National Institutes of Health (NIH) and Astrazeneca plc have demonstrated that targeting the pre-F protein led to better protection. No more bets on RSV immunization based on the post-F protein of the virus. Laboratories can now bet all on red for the pre-F technology.
The most common cause of anemia in chronically ill hospitalized patients is due to inflammatory anemia (IA) that is caused indirectly by diseases such as autoimmune, cancer, chronic kidney disease, congestive heart failure, or pulmonary disease. The precise and common etiology of these diseases involves hypercytokinemia that leads to excessive increases in hepcidin, a master regulator of iron homeostasis that blocks intestinal iron absorption when levels are too persistently high.
The hepatitis C virus (HCV) is so common that it infects approximately 0.7% of the world population to ultimately cause ~300,000 deaths each year. Small molecule-based antivirals can cure most HCV infections, but these are often only used after irreversible liver damage has already occurred, prohibitively expensive, and inaccessible for high-risk populations.
The controlled cell death process of apoptosis functions as the first step to any full recovery from injury or disease. In the second step of any recovery process, dead cells are cleared by efferocytosis, a process performed by phagocytotic cells like macrophages. Approximately 200-300 billion apoptotic cells are cleared daily by efferocytosis starting with the recognition of newly extracellular facing phosphatidylserine (PtdSer) by PtdSer-binding proteins present on phagocytotic cells.
Eleven vaccines have now been approved by the World Health Organization for preventing COVID-19, but all exhibit drastically reduced activities after 6 months. Unlike vaccines that express only the spike protein as the immunogen, live attenuated vaccines have the potential to confer a broader and more durable protection.
RSS
